Luminate Medical, an innovative healthcare technology company headquartered in Galway, Ireland, has successfully raised €2.5 million in its latest funding round. This financing marks a significant milestone for the company as it continues its mission to revolutionize cancer care by developing groundbreaking devices aimed at alleviating the side effects of chemotherapy and facilitating home-based treatments for patients. Luminate Medical is at the forefront of this challenge with its flagship product, Lily, a pioneering device designed to prevent chemotherapy-induced hair loss in a manner that is both comfortable and portable. Additionally, the company is also working on Lilac, the world’s first preventative treatment for peripheral neuropathy, as well as a promising pipeline of projects focused on enhancing remote cancer care capabilities. With the backing of Y Combinator (S21) and a series of successful grant and investment rounds, Luminate Medical is well-positioned to lead advancements in oncology care. The recent funding will be strategically utilized to accelerate the development of their innovative devices, enhance product testing, and expand their outreach to ensure that patients have access to effective and compassionate care options from the comfort of their homes. As Luminate Medical continues to pursue its vision of making cancer treatments more manageable for patients, this fresh capital will help to solidify their place as trailblazers in the healthcare tech landscape.








